600196 复星医药
2025/122024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)7.0225.9605.2878.90612.413
总资产报酬率 ROA (%)2.8382.3992.1633.7225.343
投入资产回报率 ROIC (%)3.6183.0562.7584.8446.946

边际利润分析
销售毛利率 (%)50.07447.97447.83747.28448.144
营业利润率 (%)12.55010.3377.98910.59516.156
息税前利润/营业总收入 (%)15.03912.85610.26311.88116.679
净利润/营业总收入 (%)10.1968.5536.9938.98112.756

收益指标分析
经营活动净收益/利润总额(%)30.79640.0473.53756.95431.740
价值变动净收益/利润总额(%)67.32247.69894.18141.08782.350
营业外收支净额/利润总额(%)-2.276-1.819-1.315-1.799-4.301

偿债能力分析
流动比率 (X)0.9290.9211.0011.0591.038
速动比率 (X)0.7570.7270.7780.8530.851
资产负债率 (%)48.49048.97550.10449.50848.150
带息债务/全部投入资本 (%)38.01237.96038.27337.44735.137
股东权益/带息债务 (%)135.483135.770133.295142.559158.135
股东权益/负债合计 (%)83.72982.15580.35584.03187.243
利息保障倍数 (X)5.4324.7544.3178.06614.022

营运能力分析
应收账款周转天数 (天)74.81768.35766.22655.77148.883
存货周转天数 (天)116.923124.656120.19495.98394.631